Literature DB >> 22644835

Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency.

Linman Li1, Wei Ren, Jinchao Li, Jingjing Liu, Lingli Wang, Xiaoya Zheng, Dezhen Liu, Sufang Li, Rhonda Souvenir, Jiping Tang.   

Abstract

Adult Growth Hormone Deficiency (AGHD) is correlated to many adverse effects on metabolism and increased cardiovascular risk. Pregnancy-associated plasma protein-A (PAPP-A) is a protease that promotes IGF-I availability in vascular tissues in recent study, and PAPP-A levels have been proposed as an early predictor of cardiac events. The aim of our study was to compare PAPP-A levels in AGHD patients with that of healthy adult subjects to determine if there is a relationship between serum PAPP-A and glucose and lipid metabolism. Twenty AGHD patients and 20 healthy, age-matched and weight-matched persons were chosen for the study. Their weight, height, blood pressure, body mass index (BMI), body fat percentage, waist and hip circumference, and waist-hips ratio were assessed. An oral glucose tolerance test was performed and venous blood was collected from the each patient's cubital vein for biochemical analysis. Serum PAPP-A level in AGHD patients was significantly higher than that of the control group [(7.62 ± 1.62 vs. 6.54 ± 1.31) p < 0.05], and PAPP-A was positively correlated to age, BMI, waist circumference and so on. After adjusting for the waist circumference, waist-hip ratio, 2 h postprandial blood glucose, triglycerides, the serum PAPP-A in AGHD patients was positively correlated to the BMI (r = 0.728, p < 0.05) and fasting insulin (r = 0.433, p < 0.05). In a multiple step-wise regression analysis, BMI, 2 h postprandial glucose, fasting insulin, HOMA-IR were independently associated with serum PAPP-A in AGHD patients. The increase in serum PAPP-A levels is associated with abnormal glucose metabolism and increased risk of atherosclerosis in AGHD patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644835     DOI: 10.1007/s12020-012-9697-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  36 in total

Review 1.  Cardiovascular risk in aging and obesity: is there a role for GH.

Authors:  M Gola; S Bonadonna; M Doga; G Mazziotti; A Giustina
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

2.  Overnight metabolic fuel deficiency in patients treated conventionally for hypopituitarism.

Authors:  K A Al-Shoumer; K Ali; V Anyaoku; R Niththyananthan; D G Johnston
Journal:  Clin Endocrinol (Oxf)       Date:  1996-08       Impact factor: 3.478

3.  Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: expression in human reproductive and nonreproductive tissues.

Authors:  M T Overgaard; C Oxvig; M Christiansen; J B Lawrence; C A Conover; G J Gleich; L Sottrup-Jensen; J Haaning
Journal:  Biol Reprod       Date:  1999-10       Impact factor: 4.285

4.  Cytokine stimulation of pregnancy-associated plasma protein A expression in human coronary artery smooth muscle cells: inhibition by resveratrol.

Authors:  Cheryl A Conover; Laurie K Bale; Sean C Harrington; Zachary T Resch; Michael T Overgaard; Claus Oxvig
Journal:  Am J Physiol Cell Physiol       Date:  2006-01       Impact factor: 4.249

Review 5.  Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study.

Authors:  Rasmus Sode-Carlsen; Stense Farholt; Kai Fr Rabben; Jens Bollerslev; Thomas Schreiner; Anne Grethe Jurik; Jens Sandahl Christiansen; Charlotte Höybye
Journal:  Endocrine       Date:  2011-11-12       Impact factor: 3.633

Review 6.  Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy.

Authors:  Annamaria Colao; Carolina Di Somma; Maria Cristina Savanelli; Monica De Leo; Gaetano Lombardi
Journal:  Growth Horm IGF Res       Date:  2006-05-11       Impact factor: 2.372

7.  Measurement of oxidative stress and endothelial dysfunction in patients with hypopituitarism and severe deficiency adult growth hormone deficiency.

Authors:  Daniel González-Duarte; Ainara Madrazo-Atutxa; Alfonso Soto-Moreno; Alfonso Leal-Cerro
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

8.  Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Authors:  Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

9.  Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy.

Authors:  J Svensson; B-A Bengtsson; T Rosén; A Odén; G Johannsson
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

10.  Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study.

Authors:  Anders Juul; Thomas Scheike; Michael Davidsen; Jesper Gyllenborg; Torben Jørgensen
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

View more
  10 in total

1.  Cardiovascular risk factors in growth hormone deficiency: is vitamin D a new kid on the block?

Authors:  Jörgen Isgaard
Journal:  Endocrine       Date:  2016-01-14       Impact factor: 3.633

Review 2.  The metabolic effects of growth hormone in adipose tissue.

Authors:  Valéria Ernestânia Chaves; Fernando Mesquita Júnior; Gisele Lopes Bertolini
Journal:  Endocrine       Date:  2013-02-21       Impact factor: 3.633

3.  Growth hormone deficiency and cardiovascular risk: do we need additional markers?

Authors:  M Gola; A Giustina
Journal:  Endocrine       Date:  2012-10       Impact factor: 3.633

Review 4.  Unusual effects of GH deficiency in adults: a review about the effects of GH on skin, sleep, and coagulation.

Authors:  F Tanriverdi; Z Karaca; K Unluhizarci; F Kelestimur
Journal:  Endocrine       Date:  2014-05-11       Impact factor: 3.633

5.  Association between Visceral Fat and Bone Mineral Density in Both Male and Female Patients with Adult Growth Hormone Deficiency.

Authors:  Linman Li; Li Zhong; Xiaoya Zheng; Wenyi You; Yunting Wang; Jihui Yu; Xun Wu; Wei Ren; Gangyi Yang
Journal:  Biochem Res Int       Date:  2020-07-05

6.  Preferential impact of pregnancy-associated plasma protein-A deficiency on visceral fat in mice on high-fat diet.

Authors:  Cheryl A Conover; Sara L Harstad; Tamar Tchkonia; James L Kirkland
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-09-17       Impact factor: 4.310

Review 7.  Treatment of adult growth hormone deficiency with human recombinant growth hormone: an update on current evidence and critical review of advantages and pitfalls.

Authors:  Ana M Ramos-Leví; Mónica Marazuela
Journal:  Endocrine       Date:  2018-02-07       Impact factor: 3.633

Review 8.  GH and the cardiovascular system: an update on a topic at heart.

Authors:  Jörgen Isgaard; Michele Arcopinto; Kristjan Karason; Antonio Cittadini
Journal:  Endocrine       Date:  2014-06-28       Impact factor: 3.633

Review 9.  Growth Hormone (GH) and Cardiovascular System.

Authors:  Diego Caicedo; Oscar Díaz; Pablo Devesa; Jesús Devesa
Journal:  Int J Mol Sci       Date:  2018-01-18       Impact factor: 5.923

Review 10.  Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile.

Authors:  Balázs Ratku; Veronika Sebestyén; Annamária Erdei; Endre V Nagy; Zoltán Szabó; Sándor Somodi
Journal:  Pituitary       Date:  2022-02-01       Impact factor: 4.107

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.